Arch Biopartners' AB569 Receives Positive Opinion from EMA

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Arch Biopartners' AB569 Receives Positive Opinion from EMA COMP for Orphan Designation for Cystic Fibrosis

TORONTO, ONTARIO--(Marketwired - April 26, 2016) - Arch Biopartners Inc. (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced the European Medicines Authority (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending AB569 for designation as an orphan medicinal product for the treatment of patients with cystic fibrosis (CF).

The orphan medicinal products designation is recommended for the two active ingredients of AB569, sodium nitrite and ethylenediaminetetraacetic acid (EDTA). AB569 was invented by Dr. Daniel Hassett at the University of Cincinnati College of Medicine to treat antibiotic resistant bacterial lung infections, which is a significant problem for patients with CF. "This very positive development will serve to accelerate our transition into CF clinical trials that are already planned at the University of Cincinnati and Cincinnati Children's Hospital," said Dr. Hassett.

"The positive opinion by the COMP in favour of orphan medicinal status for the treatment of CF is indicative of the clinical need to combat antibiotic resistant airway infections often found in CF patients," said Dr. Daniel Muruve, Chief Science Officer of Arch.

The COMP's positive opinion will be forwarded to the European Commission (EC) for final approval of the orphan designation for AB569, expected to be completed in the next few weeks.

The U.S. Food and Drug Administration (FDA) recently granted Orphan Drug Designation for AB569 in the treatment of antibiotic resistant Pseudomonas aeruginosa ( P. aeruginosa) pulmonary infections in patients with CF.

Arch has recently arranged the manufacturing and toxicology program for AB569 and plans to submit an investigational new drug application to the FDA in the second half of 2016.

The Need for a New Treatment for P. aeruginosa Pulmonary Infections in CF patients

P. aeruginosa is a significant cause of bacterial respiratory infections in patients who have cystic fibrosis or chronic obstructive pulmonary disease (COPD). It is also a common cause of pneumonia.

Cystic fibrosis patients are predisposed to lung infections due to abnormal mucus production in the lungs and airways. P. aeruginosa infects 40% of CF patients between the ages of 6 and 10 years of age. By the age of 17, the frequency of infection increases to 60% and reaches approximately 75% of all CF patients between the ages of 25 and 34.

The mean prevalence of cystic fibrosis is approximately 0.74 cases per 10,000 people among 27 European Union countries, which is well below the defined limit for a rare or orphan disease. The mucoid form of P. aeruginosa , often found in CF patients, is a very challenging infection to treat due to its high resistance to both antibiotics and phagocyte-mediated killing. Once patients present with the mucoid form of P. aeruginosa , their overall lung function precipitously declines, resulting in a poor prognosis. AB569 constitutes an innovative potential treatment for dealing with mucoid and nonmucoid P. aeruginosa pulmonary infections that are resistant to traditional antibiotics.

About Arch Biopartners

Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.

Arch has established a diverse portfolio that includes MetaMx, which targets illusive brain tumor initiating cells; AB569, a potential new treatment for Pseudomonas aeruginosa pulmonary infections; and, Metablok, a potential treatment for sepsis and cancer metastasis.

For more information on Arch Biopartners, other public documents Arch has filed on SEDAR and its technologies including, please visit www.archbiopartners.com

The Company has 53,189,679 common shares outstanding.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Arch Biopartners Inc. Richard Muruve Chief Executive Officer 647-428-7031 info@archbiopartners.com www.archbiopartners.com Virtus Advisory Group Inc. Babak Pedram Investor Relations 416-644-5081 bpedram@virtusadvisory.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

RCA Mount Dora Widens Addiction Care Insurance Reach

Updated Category News Views 81

Insurance paperwork rarely looks heroic, yet it can decide whether treatment starts before a crisis gets worse. Recovery Centers of America at Mount Dora has added Aetna and Cigna/Evernorth to its in-network roster for every level of substance use disorder care, a practical move with real consequences for patients and families across Central Florida. Coverage matters most...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 192

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 117

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 160

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
NEDHSA Amplifies Tobacco-Free Push with 2026 Smokeout

Updated Category News Views 87

2026 Great American Smokeout: A Fresh Push Against Tobacco NEDHSA is sticking to its guns with a tobacco-free campaign that’s got deep roots. The 2026 Great American Smokeout, on November 19, not only highlights past efforts but looks to stir more folks into healthier habits. Beyond the campaign glitz, it’s about dragging a century-long bad habit further into the...

Continue Reading
Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 184

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 171

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 190

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 132

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading
Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 106

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading

Top 5 Most Recently Viewed Articles

Skylark Labs Enhances Mobility Analytics with New Contracts

Updated Category News Views 259

Transforming Mobility Analytics Skylark Labs is at the forefront of innovation as it takes significant strides to transform mobility analytics. The company recently announced its success in securing multiple contracts aimed at deploying its advanced Scout Towers throughout busy highways. Empowering the Indiana DOT The focus of these contracts is primarily on empowering...

Continue Reading
Arm Collaborates with Malaysia on $250 Million Chip Initiative

Updated Category News Views 201

Introduction to the Exciting Partnership Arm Holdings – ADR (NASDAQ: ARM), a dynamic subsidiary of SoftBank Group Corp. (OTC: SFTBY), has embarked on a groundbreaking partnership with Malaysia, sealing a monumental $250 million deal. This agreement aims to significantly enhance chip design and technology services over the next decade, marking a pivotal moment in both...

Continue Reading
Music Licensing, Inc. (OTC: SONG) Implements New Share Classes

Updated Category News Views 119

Music Licensing, Inc. Unveils New Share Classes and Forward Stock Split Music Licensing, Inc. (OTC: SONG), a well-known leader in music rights management, is making substantial moves to improve its stock market standing. Recently, the company faced some challenges, including an unsuccessful reverse stock split. In response to these hurdles, they are proactively addressing...

Continue Reading
Exploring Legal Actions for Venture Global, Inc. Investors

Updated Category News Views 368

Latest Developments for Venture Global, Inc. Investors Venture Global, Inc. is currently under scrutiny as a class-action lawsuit has been initiated on behalf of its investors. This follows significant developments surrounding the company's operations and interactions with major clients. Understanding the Class Action Lawsuit The lawsuit focuses on the concerns raised by...

Continue Reading
STL and Colt Together Pioneer Multi-Core Fibre Trials for The Future

Updated Category News Views 112

Innovation in Optical Connectivity: The STL and Colt Collaboration In a groundbreaking development, STL (NSE: STLTECH), a renowned connectivity solutions provider, has successfully partnered with Colt Technology Services to conduct trials of their innovative Multi-Core Fibre (MCF). This initiative, executed within Colt's expansive optical network in an urban setting,...

Continue Reading